| Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review AP Zavascki, LZ Goldani, J Li, RL Nation Journal of antimicrobial chemotherapy 60 (6), 1206-1215, 2007 | 996 | 2007 |
| International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical … BT Tsuji, JM Pogue, AP Zavascki, M Paul, GL Daikos, A Forrest, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (1 …, 2019 | 691 | 2019 |
| Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy AP Zavascki, CG Carvalhaes, RC Picao, AC Gales Expert review of anti-infective therapy 8 (1), 71-93, 2010 | 569 | 2010 |
| Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens AM Sandri, CB Landersdorfer, J Jacob, MM Boniatti, MG Dalarosa, ... Clinical infectious diseases 57 (4), 524-531, 2013 | 437 | 2013 |
| Pharmacokinetics of intravenous polymyxin B in critically ill patients AP Zavascki, LZ Goldani, G Cao, SV Superti, L Lutz, AL Barth, F Ramos, ... Clinical infectious diseases 47 (10), 1298-1304, 2008 | 271 | 2008 |
| Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? AP Zavascki, RL Nation Antimicrobial agents and chemotherapy 61 (3), 10.1128/aac. 02319-16, 2017 | 205 | 2017 |
| Combination therapy for carbapenem-resistant Gram-negative bacteria AP Zavascki, JB Bulitta, CB Landersdorfer Expert review of anti-infective therapy 11 (12), 1333-1353, 2013 | 186 | 2013 |
| Clinical Characteristics of Covid-19 in China. AP Zavascki, DR Falci World 727, 33, 2020 | 168 | 2020 |
| Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium FF Tuon, MH Rigatto, CK Lopes, LK Kamei, JL Rocha, AP Zavascki International journal of antimicrobial agents 43 (4), 349-352, 2014 | 168 | 2014 |
| The influence of metallo-β-lactamase production on mortality in nosocomial Pseudomonas aeruginosa infections AP Zavascki, AL Barth, ALS Gonçalves, ALD Moro, JF Fernandes, ... Journal of Antimicrobial Chemotherapy 58 (2), 387-392, 2006 | 155 | 2006 |
| The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic LS Elias, D Konzen, JM Krebs, AP Zavascki Journal of antimicrobial chemotherapy 65 (10), 2231-2237, 2010 | 146 | 2010 |
| Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B MH Rigatto, MS Oliveira, LV Perdigão-Neto, AS Levin, CM Carrilho, ... Antimicrobial agents and chemotherapy 60 (4), 2443-2449, 2016 | 139 | 2016 |
| Reduction in Inddence of Nosocomial Methicillin-Resistant Staphylococcus aureus (MRSA) Infection in an Intensive Care Unit: Role of Treatment With Mupirocin … AM Sandri, MG Dalarosa, LR de Alcântara, L da Silva Elias, AP Zavascki Infection Control & Hospital Epidemiology 27 (2), 185-187, 2006 | 131 | 2006 |
| Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case–control studies in hospitalized patients AP Zavascki, RP Cruz, LZ Goldani Journal of Hospital Infection 59 (2), 96-101, 2005 | 128 | 2005 |
| Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study MH Rigatto, TF Behle, DR Falci, T Freitas, NT Lopes, M Nunes, LW Costa, ... Journal of Antimicrobial Chemotherapy 70 (5), 1552-1557, 2015 | 126 | 2015 |
| Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing SPM-1 metallo-β-lactamase in a teaching hospital in southern Brazil AP Zavascki, PB Gaspareto, AF Martins, AL Goncalves, AL Barth Journal of Antimicrobial Chemotherapy 56 (6), 1148-1151, 2005 | 125 | 2005 |
| Polymyxin acute kidney injury: dosing and other strategies to reduce toxicity RL Nation, MHP Rigatto, DR Falci, AP Zavascki Antibiotics 8 (1), 24, 2019 | 110 | 2019 |
| Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-β-lactamase-mediated multidrug resistance: a prospective … AP Zavascki, AL Barth, JF Fernandes, ALD Moro, ALS Gonçalves, ... Critical care 10, 1-7, 2006 | 108 | 2006 |
| Diretrizes para o tratamento farmacológico da COVID-19. Consenso da Associação de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade … M Falavigna, V Colpani, C Stein, LCP Azevedo, AM Bagattini, GV Brito, ... Revista Brasileira de Terapia Intensiva 32, 166-196, 2020 | 105 | 2020 |
| Emergence of NDM-1-producing Enterobacteriaceae in Porto Alegre, Brazil FP Rozales, VB Ribeiro, CM Magagnin, M Pagano, L Lutz, DR Falci, ... International Journal of Infectious Diseases 25, 79-81, 2014 | 86 | 2014 |
